Arbutus Biopharma Corporation (ABUS) Income Statement Analysis

See more : Maisons du Monde S.A. (MDM.PA) Income Statement Analysis – Financial Results

Complete financial analysis of Arbutus Biopharma Corporation (ABUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arbutus Biopharma Corporation, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Arbutus Biopharma Corporation (ABUS)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.arbutusbio.com

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	18.14M	39.02M	10.99M	6.91M	6.01M	5.90M	10.70M	1.50M	24.87M	15.00M	15.46M	14.18M	16.30M	21.35M	13.78M	9.64M	15.92M	13.60M	13.29M	12.17M	2.73M	5.07M	3.46M	1.77M	1.14M	1.23M
Cost of Revenue	73.70M	1.43M	1.75M	47.48M	57.60M	57.90M	62.70M	61.30M	51.51M	38.70M	21.46M	18.13M	19.49M	22.13M	16.97M	13.25M	0.00	6.19M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-55.56M	37.59M	9.24M	-40.57M	-51.59M	-52.00M	-52.00M	-59.80M	-26.63M	-23.70M	-5.99M	-3.94M	-3.19M	-779.12K	-3.19M	-3.61M	15.92M	7.42M	13.29M	12.17M	2.73M	5.07M	3.46M	1.77M	1.14M	1.23M
Gross Profit Ratio	-306.26%	96.34%	84.05%	-586.74%	-858.26%	-881.36%	-485.98%	-3,986.67%	-107.07%	-158.00%	-38.76%	-27.82%	-19.54%	-3.65%	-23.12%	-37.43%	100.00%	54.53%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Research & Development	73.70M	84.41M	65.50M	47.48M	57.60M	57.90M	62.70M	61.30M	51.51M	38.70M	21.46M	18.13M	0.00	22,133.98B	0.00	0.00	8.43M	4.53M	8.76M	22.32M	23.71M	21.61M	12.85M	8.72M	7.75M	8.65M
General & Administrative	22.48M	17.83M	17.14M	14.72M	17.73M	16.00M	16.10M	39.40M	26.44M	8.70M	5.55M	26.89M	0.00	4.78M	3.97M	0.00	4.44M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	22.48M	17.83M	17.14M	14.72M	17.73M	16.00M	16.10M	39.40M	26.44M	8.70M	5.55M	26.89M	6.18M	4.78M	3.97M	3.62M	4.44M	3.85M	3.78M	7.76M	6.78M	5.52M	3.10M	2.25M	1.57M	1.33M
Other Expenses	0.00	2.23M	1.87M	1.98M	2.03M	7.30M	2.20M	2.50M	-770.00K	-5.80M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	96.24M	102.24M	82.64M	64.18M	77.36M	76.10M	80.80M	101.80M	78.53M	47.90M	27.62M	-19.49M	7.14M	11.73M	5.88M	4.73M	13.28M	9.10M	14.38M	35.55M	37.38M	32.79M	19.87M	10.97M	9.31M	9.98M
Cost & Expenses	96.24M	102.24M	82.64M	64.18M	77.36M	76.10M	80.80M	101.80M	78.53M	47.90M	27.62M	-19.49M	26.63M	33.86M	22.85M	17.98M	13.28M	15.29M	14.38M	35.55M	37.38M	32.79M	19.87M	10.97M	9.31M	9.98M
Interest Income	5.69M	2.19M	127.00K	741.00K	2.11M	3.00M	1.54M	1.39M	674.00K	853.00K	540.00K	138.95K	122.28K	106.94K	156.33K	738.37K	1.02M	316.81K	439.39K	750.85K	1.14M	1.02M	1.03M	0.00	0.00	0.00
Interest Expense	459.00K	1.73M	2.86M	4.01M	2.11M	200.00K	261.00K	0.00	0.00	0.00	0.00	47.00K	76.91K	0.00	0.00	0.00	0.00	1.61M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.40M	1.43M	1.75M	1.98M	2.03M	2.18M	2.03M	1.09M	589.00K	500.00K	612.84K	869.54K	955.45K	1.04M	1.91M	1.11M	411.65K	599.77K	2.40M	1.20M	6.80M	5.59M	3.85M	1.26M	1.30M	989.78K
EBITDA	-70.99M	-61.86M	-71.64M	-57.81M	-147.32M	-58.95M	-106.45M	-488.07M	-76.72M	-32.44M	-11.54M	34.18M	-9.06M	-11.05M	-6.74M	-7.23M	3.05M	20.97M	1.31M	-17.90M	-27.76M	-22.06M	-12.57M	-9.41M	-6.87M	-7.76M
EBITDA Ratio	-391.30%	-156.41%	-650.92%	-825.79%	-1,489.85%	-1,072.88%	-255.14%	19,473.33%	-118.68%	-216.00%	-58.78%	270.46%	-60.33%	-53.71%	-48.88%	-32.29%	25.58%	-7.06%	45.45%	-129.31%	-1,016.02%	-434.95%	-374.23%	-449.45%	-602.29%	-632.58%
Operating Income	-78.10M	-65.46M	-73.52M	-57.81M	-144.07M	-89.80M	-110.90M	-491.60M	-102.32M	-33.00M	-12.15M	-12.99M	-10.32M	-12.51M	-9.07M	-10.95M	2.64M	-1.68M	-5.96M	-27.63M	-34.65M	-27.72M	-16.41M	-9.20M	-8.17M	-8.75M
Operating Income Ratio	-430.53%	-167.75%	-669.11%	-836.07%	-2,396.84%	-1,522.03%	-1,036.45%	-32,773.33%	-411.38%	-220.00%	-78.59%	-91.62%	-63.32%	-58.61%	-65.79%	-113.58%	16.57%	-12.36%	-44.83%	-227.08%	-1,268.10%	-546.46%	-474.40%	-520.56%	-716.68%	-713.22%
Total Other Income/Expenses	5.25M	444.00K	-2.73M	-5.94M	-22.48M	28.44M	2.20M	2.47M	25.02M	-5.40M	-1.91M	42.56M	574.19K	-5.65M	-466.28K	-769.07K	-5.22M	19.76M	-6.49M	-4.03M	0.00	0.00	455.26K	0.00	0.00	0.00
Income Before Tax	-72.85M	-65.01M	-76.25M	-63.75M	-166.38M	-61.40M	-108.70M	-489.10M	-77.31M	-38.70M	-14.06M	29.95M	-9.85M	-12.52M	-9.48M	-11.72M	-2.58M	18.08M	-7.67M	-29.80M	0.00	0.00	-15.96M	0.00	0.00	0.00
Income Before Tax Ratio	-401.57%	-166.62%	-693.91%	-921.97%	-2,767.91%	-1,040.68%	-1,015.89%	-32,606.67%	-310.80%	-258.00%	-90.95%	211.19%	-60.44%	-58.64%	-68.81%	-121.56%	-16.22%	132.89%	-57.72%	-244.89%	0.00%	0.00%	-461.24%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	4.44M	1.10M	1.47M	-12.66M	-4.30M	-24.30M	-105.00M	-16.19M	100.00K	1.91M	3.72M	-590.69K	-99.82K	259.76K	3.38M	0.00	-2.31K	388.32K	8.95M	-483.80K	-852.14K	-2.33M	0.00	0.40	0.03
Net Income	-72.85M	-69.46M	-77.35M	-65.21M	-153.72M	-57.10M	-84.40M	-384.10M	-61.12M	-38.80M	-14.06M	29.95M	-9.73M	-12.41M	-9.33M	-11.72M	-2.58M	18.08M	-8.06M	-28.05M	-34.08M	-26.79M	-14.02M	-9.20M	-8.17M	-8.75M
Net Income Ratio	-401.57%	-178.01%	-703.96%	-943.17%	-2,557.36%	-967.80%	-788.79%	-25,606.67%	-245.73%	-258.67%	-90.95%	211.19%	-59.69%	-58.14%	-67.68%	-121.56%	-16.22%	132.90%	-60.64%	-230.49%	-1,247.26%	-528.27%	-405.13%	-520.56%	-716.68%	-713.22%
EPS	-0.44	-0.46	-0.73	-0.86	-2.69	-1.03	-1.54	-7.24	-1.34	-1.80	-0.92	2.16	-0.86	-1.20	-0.90	-1.44	-0.54	4.68	-1.04	-3.64	-4.78	-4.08	-2.76	-1.87	-2.90	-4.05
EPS Diluted	-0.44	-0.46	-0.73	-0.86	-2.69	-1.03	-1.54	-7.24	-1.34	-1.73	-0.92	2.07	-0.86	-1.20	-0.90	-1.44	-0.54	4.68	-1.04	-3.64	-4.78	-4.08	-2.76	-1.87	-2.90	-4.05
Weighted Avg Shares Out	165.96M	150.94M	106.24M	75.84M	57.09M	55.30M	54.69M	53.05M	45.45M	21.58M	15.29M	13.73M	11.32M	10.33M	10.33M	8.12M	4.77M	3.86M	7.71M	7.70M	7.13M	6.57M	5.07M	4.93M	2.82M	2.16M
Weighted Avg Shares Out (Dil)	165.96M	150.94M	106.24M	75.84M	57.09M	55.30M	54.72M	53.05M	45.46M	22.44M	15.30M	14.32M	11.32M	10.33M	10.33M	8.12M	4.77M	3.86M	7.71M	7.70M	7.13M	6.57M	5.07M	4.93M	2.82M	2.16M

What's the Outlook for Arbutus Biopharma?

February 5, 2022fool.com

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

January 4, 2022globenewswire.com

WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people...

Roivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy Arbutus

December 21, 2021seekingalpha.com

ROIV has moved up 88% in December in reaction to a patent dispute between Moderna and Arbutus falling in favor of Arbutus. The patent is licensed to a private company called Genevant. ROIV owns an effective 88% stake through direct...

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

December 17, 2021seekingalpha.com

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company with research specialization in chronic hepatitis B virus (HBV). In December 2021, ABUS reported its victory in the patent dispute over Moderna, involving its licensed four-lipid nanoparticles delivery system.

Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets

December 14, 2021pennystocks.com

5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Arbutus Biopharma Shares Are Rising

December 13, 2021benzinga.com

Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia. William Collier, President and Chief Executive Officer of Arbutus Biopharma, commented, "Qilu is an ideal partner...